Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
QURE uniQure	$13.86 -0.8%	$11.95	$3.73 ▼ $19.18	$749.51M	0.42	1.77 million shs	647,879 shs
RCKT Rocket Pharmaceuticals	$7.28 +1.7%	$7.50	$4.55 ▼ $26.98	$776.27M	1	1.33 million shs	1.42 million shs
XNCR Xencor	$10.58 -0.2%	$11.66	$7.16 ▼ $27.24	$752.79M	0.9	626,975 shs	540,900 shs
YMAB Y-mAbs Therapeutics	$4.20 -0.7%	$4.79	$3.84 ▼ $17.78	$189.92M	0.71	327,420 shs	152,403 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
QURE uniQure	-1.48%	+5.12%	+12.03%	-8.81%	+208.39%
RCKT Rocket Pharmaceuticals	-0.97%	-0.14%	-5.67%	-32.33%	-67.42%
XNCR Xencor	+0.86%	0.00%	-5.61%	-45.08%	-46.95%
YMAB Y-mAbs Therapeutics	+3.17%	-12.24%	-12.06%	-30.54%	-71.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
QURE uniQure	2.3835 of 5 stars	3.4	2.0	0.0	2.3	2.5	0.6
RCKT Rocket Pharmaceuticals	4.6404 of 5 stars	4.5	1.0	4.7	2.0	5.0	0.6
XNCR Xencor	3.3583 of 5 stars	3.6	0.0	3.9	2.1	0.0	1.3
YMAB Y-mAbs Therapeutics	3.6653 of 5 stars	4.4	3.0	0.0	1.7	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
QURE uniQure	2.82	Moderate Buy	$38.80	179.94% Upside
RCKT Rocket Pharmaceuticals	2.92	Moderate Buy	$43.00	490.66% Upside
XNCR Xencor	3.13	Buy	$33.86	220.01% Upside
YMAB Y-mAbs Therapeutics	2.82	Moderate Buy	$17.40	314.29% Upside

Current Analyst Ratings Breakdown

Latest YMAB, RCKT, QURE, and XNCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/22/2025	YMAB Y-mAbs Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00
4/21/2025	QURE uniQure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
4/21/2025	XNCR Xencor	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/9/2025	RCKT Rocket Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
4/1/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$27.00 ➝ $38.00
3/21/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $12.00
3/12/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
3/5/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $18.00
3/5/2025	YMAB Y-mAbs Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00
3/5/2025	YMAB Y-mAbs Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$11.00 ➝ $7.00
3/4/2025	QURE uniQure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
QURE uniQure	$27.12M	27.64	N/A	N/A	$4.34 per share	3.19
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A
XNCR Xencor	$110.49M	6.81	N/A	N/A	$10.99 per share	0.96
YMAB Y-mAbs Therapeutics	$87.69M	2.17	N/A	N/A	$2.32 per share	1.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
QURE uniQure	-$308.48M	-$4.93	N/A	N/A	N/A	-837.80%	-188.82%	-32.17%	5/6/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.73	N/A	N/A	N/A	N/A	-62.62%	-54.17%	5/5/2025 (Estimated)
XNCR Xencor	-$126.09M	-$3.51	N/A	N/A	N/A	-232.77%	-30.92%	-21.74%	5/8/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$21.43M	-$0.67	N/A	N/A	N/A	-28.22%	-24.61%	-18.49%	5/6/2025 (Estimated)

Latest YMAB, RCKT, QURE, and XNCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	XNCR Xencor	-$0.60	N/A	N/A	N/A	$23.44 million	N/A
5/6/2025	Q1 2025	QURE uniQure	-$1.07	N/A	N/A	N/A	N/A	N/A
5/6/2025	Q1 2025	YMAB Y-mAbs Therapeutics	-$0.21	N/A	N/A	N/A	$19.97 million	N/A
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	N/A	N/A	N/A	$0.80 million	N/A
3/4/2025	Q4 2024	YMAB Y-mAbs Therapeutics	-$0.13	-$0.15	-$0.02	-$0.15	$26.70 million	$26.50 million
3/3/2025	Q4 2024	RCKT Rocket Pharmaceuticals	-$0.68	-$0.62	+$0.06	-$0.62	$0.03 million	N/A
2/27/2025	Q4 2024	XNCR Xencor	-$0.81	-$0.62	+$0.19	-$0.62	$17.14 million	$52.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
QURE uniQure	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
QURE uniQure	0.92	6.51	6.51
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05
XNCR Xencor	0.01	6.23	6.23
YMAB Y-mAbs Therapeutics	N/A	3.92	3.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
QURE uniQure	78.83%
RCKT Rocket Pharmaceuticals	98.39%
XNCR Xencor	N/A
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
QURE uniQure	4.74%
RCKT Rocket Pharmaceuticals	28.50%
XNCR Xencor	5.23%
YMAB Y-mAbs Therapeutics	22.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
QURE uniQure	500	54.08 million	46.43 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.63 million	65.18 million	Optionable
XNCR Xencor	280	71.15 million	66.32 million	Optionable
YMAB Y-mAbs Therapeutics	150	45.22 million	34.71 million	Optionable

YMAB, RCKT, QURE, and XNCR Headlines

Recent News About These Companies

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline

April 29 at 11:05 AM | zacks.com

Boothbay Fund Management LLC Buys 136,264 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

April 29 at 6:24 AM | marketbeat.com

Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA

April 28 at 12:06 AM | markets.businessinsider.com

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measures

April 27 at 7:05 PM | finance.yahoo.com

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

April 27 at 3:00 PM | globenewswire.com

Brookline Capital Management Weighs in on YMAB Q1 Earnings

April 27 at 6:29 AM | marketbeat.com

Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platform

April 26 at 8:59 AM | markets.businessinsider.com

YMAB Q1 EPS Estimate Reduced by Brookline Capital Management

April 26 at 1:17 AM | americanbankingnews.com

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma

April 25, 2025 | globenewswire.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded to "Underperform" Rating by Bank of America

April 24, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Underperform" at Bank of America

April 24, 2025 | americanbankingnews.com

Y-mAbs Therapeutics downgraded to Underperform from Neutral at BofA

April 23, 2025 | markets.businessinsider.com

Y-mAbs downgraded to Underperform at BofA on tough near-term setup

April 23, 2025 | markets.businessinsider.com

Y-mAbs drops as Bank of America downgrades on headwinds to Danyelza

April 23, 2025 | msn.com

Why Y-mAbs Therapeutics, Inc.’s (YMAB) Stock Is Down 7.47%

April 23, 2025 | aaii.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Moderate Buy" from Analysts

April 21, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Update

April 21, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Moderate Buy" from Brokerages

April 20, 2025 | americanbankingnews.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Down 17.6% in March

April 20, 2025 | americanbankingnews.com

Y-mAbs Therapeutics, Inc.

April 16, 2025 | cnn.com

Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity

April 11, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

YMAB, RCKT, QURE, and XNCR Company Descriptions

uniQure NASDAQ:QURE

$13.86 -0.11 (-0.79%)

Closing price 04:00 PM Eastern

Extended Trading

$13.82 -0.04 (-0.25%)

As of 07:22 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Rocket Pharmaceuticals NASDAQ:RCKT

$7.28 +0.12 (+1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$7.31 +0.03 (+0.47%)

As of 07:05 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Xencor NASDAQ:XNCR

$10.58 -0.02 (-0.19%)

Closing price 04:00 PM Eastern

Extended Trading

$10.76 +0.19 (+1.75%)

As of 05:52 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

Y-mAbs Therapeutics NASDAQ:YMAB

$4.20 -0.03 (-0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$4.10 -0.10 (-2.36%)

As of 04:27 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time